Matt Hummer | IdentifySensor: Why is screen printing considered the most scalable printing method for diagnostics?

How do you scale a screen-printed graphene biosensor while ensuring quality and consistency?

The scalable manufacturing process for these graphene sensors is broken down into three major phases. The first phase involves evaluating raw graphene materials and formulating them into specialized inks, which presents its own set of challenges. The second phase focuses on achieving print uniformity to ensure that the screen-printing process delivers highly controlled and consistent sensor units. The final phase is the precise immobilization of the biological probe onto the graphene surface, which is critical for the sensor's ultimate performance.

Overcoming the challenges in the first phase requires addressing well-known issues in the graphene space like agglomeration, rheology, and batch-to-batch consistency. The company has developed proprietary ink formulas and, more importantly, very tight process controls and evaluation protocols to ensure every formulation is within specification. For the second phase, similar tight QC and process controls are established to mitigate the imprecision and variability that can arise from the screen-printing process itself.

The third phase, probe immobilization, is directly tied to the material stack and the production process. By developing robust characterization tools, the team can confirm proper probe immobilization, which ultimately results in the signal stability and amplitude needed for readout. To handle any remaining variability, software algorithms are used to identify abnormalities that might typically cause a false result and correct the interpretation, leading to a super high level of reproducibility.

In this short video, you can learn:
* The three critical phases of scalable graphene sensor manufacturing.
* How to manage graphene ink challenges like agglomeration and rheology.
* The role of software algorithms in compensating for manufacturing variations.
📋 **Clip Abstract** Matt Hummer details the key manufacturing challenges for their screen-printed graphene biosensors, from ink formulation to probe immobilization. He explains how a combination of tight process controls and software algorithms enables high reproducibility at scale.
🔗 Link in comments 👇

How do you achieve a 50 copies/mL limit of detection in just 5 minutes without PCR?

The Check4 platform is a software-defined digital diagnostic system designed to deliver molecular results with a five-minute sample-to-answer time. This speed and efficiency are achieved by using cloud-based algorithms that actively fine-tune both the hardware and the decision-making process. This approach fundamentally shifts molecular testing from a complex, chemical-based process to a streamlined, direct digital detection method.

By eliminating the need for enzymatic amplification and complex sample processing, the platform achieves a limit of detection of around 50 copies per milliliter. This sensitivity is on par with some of the best PCR tools available, with the exception of highly specialized digital PCR. The system's high performance has been validated across a diverse range of challenging sample types, including saliva, blood serum, plasma, and whole blood.

The platform's accessibility and low cost are rooted in a fabrication process that is entirely different from traditional semiconductor manufacturing. It utilizes a scalable screen-printing process to create the sensor cartridges and precision biomolecule deposition to functionalize them. This vertical integration of manufacturing allows the company to control the entire process, building in quality and accelerating the learning cycle required for medical device development.

In this short video, you can learn:
* The architecture of a software-defined diagnostic platform.
* How to achieve a 50 copies/mL limit of detection without amplification.
* Why screen printing enables a scalable, low-cost alternative to semiconductor fabrication.
📋 **Clip Abstract** Matt Hummer introduces the Check4 platform, which combines a screen-printed graphene cartridge with cloud-based algorithms to deliver molecular results in 5 minutes. This software-defined approach achieves a sensitivity on par with PCR (50 copies/mL) without the need for complex sample prep or amplification.
🔗 Link in comments 👇

Can an amplification-free graphene sensor really match the sensitivity of gold-standard PCR for cancer detection?

The technology is focused on a high-value clinical application: monitoring druggable cancer genes after a patient's tumor has been removed. The goal is to help clinicians monitor the response to adjuvant therapies for non-small cell lung cancer by tracking residual cancer cells. To prove its clinical utility, the platform's performance is being benchmarked against the Roche Cobas PCR system, a highly reliable and widely used platform in the field.

The results show that the amplification-free graphene sensor is meeting or exceeding the sensitivity of this gold-standard PCR platform. For key EGFR gene mutations like L858R and T790M, the technology has demonstrated a limit of detection between 50 and 150 copies per milliliter of sample. Achieving this level of sensitivity without any enzymatic amplification represents a monumental step forward for molecular detection, simplifying the entire diagnostic workflow.

Beyond matching sensitivity, the graphene sensor array offers a critical advantage in multiplexing capability. While PCR-based tests are often limited to a handful of gene targets—for example, rolling up 42 clinically relevant sequences into just seven detectable targets—this platform's architecture can detect all 42. This effectively combines the targeted sensitivity of PCR with the broad panel capabilities of next-generation sequencing into a single, rapid test.

In this short video, you can learn:
* How graphene sensors achieve a 50-150 copies/mL sensitivity for cancer mutations.
* A direct performance comparison against the Roche Cobas PCR platform.
* The multiplexing advantage that allows detection of 42 targets vs. PCR's 7.
📋 **Clip Abstract** This clip presents compelling clinical data showing an amplification-free graphene sensor matching the sensitivity of a leading PCR platform for detecting non-small cell lung cancer mutations. The technology also offers a significant multiplexing advantage, enabling a far more comprehensive genetic panel in a single test.
🔗 Link in comments 👇